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Primaquine  (PQ), a synthetic compound with potent antimalarial activity is characterized by 
low plasma half life, requiring frequent administration leading to several undesired side effects, 
patient incompliance. The objective of the present study was to design an extended release 
formulation incorporating PQ in hydrophillic matrix composed of HPMC,Sodium CMC, Sodium 
alginate. Effects of polymeric dispersions of ethyl cellulose (EC) and polyvinylpyrrolidone (PVP) 
was also studied. Tablets were prepared by wet granulation method. The results of angle of repose 
(<30) and compressiblity index (upto 15%) indicate good flow properties. Tablets were subjected 
to weight variation, hardness, friability and drug content tests. The swelling and drug release 
profile were investigated under dissolution condition. The result showed that the swelling index 
& release retarding capacity follows HPMC>Sodium CMC>Sodium alginate, which was further 
sustained by polymeric dispersions of EC and PVP. The kinetics of drugs showed extended release 
of up to 20 hrs (F3) following non fickian diffusion (0.45<n<0.89).
KEY WORDS: Primaquine phosphate, Extended release tablets, Hydroxypropylmethylcllulose, 
Sodium CMC,  Sodium alginate, Fickian
RESUMEN
La primaquina (PQ), un compuesto sintético con actividad antimalaria fuerte, se caracteriza por 
tener una vida media de plasma baja, lo que requiere una administración frecuente y provoca varios 
efectos colaterales no deseados, con inconformidad del paciente. El objetivo del estudio actual fue 
diseñar una formulación de liberación prolongada que incorpora PQ en una matriz hidrofílica 
compuesta de HPMC, CMC de sodio y alginato de sodio. Se estudiaron también los efectos de 
las dispersiones poliméricas de etilcelulosa (EC) y polivinilpirrolidona (PVP). Los comprimidos 
se prepararon según el método de granulación húmeda. Los resultados de la respuesta de ángulo 
(<30) y el índice de compresibilidad (hasta el 15%) mostraron propiedades de flujo buenas. Los 
comprimidos se sometieron a pruebas de variación de peso, dureza, friabilidad y contenido de 
fármaco. La hinchazón y el perfil de liberación del fármaco se investigaron bajo condiciones de 
disolución. Los resultados mostraron que el índice de inflamación y la capacidad retardada de 
liberación son mayores con HPMC que con CMC de sodio, y que estos a su vez son mayores que 
con alginato de sodio, los cuales fueron más sostenidos por dispersiones poliméricas de EC y PVC. 
La cinética de los fármacos mostró una liberación prolongada de hasta 20 horas (F3) siguiendo una 
difusión no de Fick (0,45<n<0,89).
PALABRAS CLAVE: Fosfato de primaquina, Comprimidos de liberación prolongada, 
Hidroxipropilmetilcelulosa, CMC de sodio, Alginato de sodio, Fickian. 
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INTRODUCTION
Primaquine  phosphate, 8-[(4-amino-1-methyl butyl)
amino]-6-metoxyquinoline phosphate, a synthetic 
compound with potent antimalarial activity is considered 
to be a prominent medicine against resurgence and is also 
prescribed for terminal prophylaxis. It shows a broad 
spectrum activity against various stages of parasite, 
particularly asexual hepatic stages and latent tissue forms. 
It is removed rapidly from blood. Excretion metabolism, 
or tissue localization account for rapid elimination of 
primaquine from the plasma1. PQ is also characterized by 
low plasma half-lives of 4-5 hrs2,3, which require frequent 
administration and amplify its adverse effects4 . The 
clinical use of primaquine for long period and repeated 
oral dosing can cause nausea, abdominal pain and 
oxidant haemolysis with methemoglobinemia, anemia, 
haemoglobinurea and is contraindicated in patients with 
different variants of glucose-6-phosphate dehydrogenase 
deficiency5. Moreover it may cause poor patient compliance 
leading to sub therapeutic primaquine concentration in 
plasma, promoting drug resistance6. In order to improve 
the therapeutic efficacy of the drug and diminish its 
toxicity, various approaches have been examined such 
as nanoparticulate system7, albumin carrier protiens8, 
nanoemulsions9 transdermal patches10. Some researchers 
have proposed high dose over short administration 
periods but PQ at high doses may affect gene expression 
in liver and produce undesirable outcomes if administered 
over long time periods11. Recently many controlled release 
formulation based on matrix system have been developed. 
These delivery systems are characterized by controlled 
release of the drug thereby reducing frequency of dosing 
& hence decreasing fluctuation of plasma levels to obtain 
better therapeutic effects with reduced toxicity.
Hydrophilic matrices are commonly used as oral drug 
delivery systems and being increasingly investigated for 
development of controlled release drug delivery system 
owing to compatibility, availability and economy. The 
release properties of matrix system may be dependent 
upon the solubility of the drug in the polymer matrix 
or in case of porous matrices, the solubility in the sink 
solution within the particles pore network12. Hydrophilic 
matrix gradually begins to hydrate from the periphery 
towards the centre forming a gelatinous swollen mass 
which controls the diffusion of drug molecules through 
polymeric materials into aqueous medium. Penetration 
by the solvent produces a clearly defined front at interface 
between the dry and hydrated form. The thickness of the 
hydrated gel layer determines the diffusional path length 
of the drug. Hence it can be optimized that if mechanism 
of release follows fickian diffusion, then rate will follow 
higuchi equation:
Q=(2ADCs t)1/2      (1)
However, diffusion is generally not the only mechanism 
controlling the release. It has been reported that in aqueous 
medium the polymer undergoes relaxation process resulting 
in slow erosion of the hydrated polymer envisaging that 
both the mechanism may work simultaneously  contributing 
to the overall release rate13 Hydroxy propyl methyl 
cellulose (HPMC) is the dominant hydrophilic vehicle 
used for the preparation of oral controlled drug delivery 
systems14 The transport phenomena involved in the drug 
release from hydrophilic matrices are complex because the 
microstructure and macrostructure of HPMC exposed to 
water is strongly time dependent. When it comes in contact 
with the gastrointestinal fluid, HPMC swells, gels, and 
finally dissolves slowly. The gel becomes a viscous layer 
acting as a protective barrier to both the influx of water and 
the efflux of the drug in solution. Numerous studies have 
been reported in literature investigating the HPMC matrices 
to control the release of a variety of drugs15,16. Sodium 
alginate have also been reported as release retarding agent 
as hydration of an alginate matrix leads to a formation 
of gelatinous layer which acts act as a diffusion barrier17.
Sodium carboxy methyl cellulose (Sodium CMC) have also 
been explored as release modifiers as it characterizes the 
properties of hydrophilic polymers18. Efforts were made 
to gain optimum zero order release, hence present study 
investigates the feasibility of incorporating polymeric 
solution of ethyl cellulose (EC) and polyvinyl pyrrolidone 
(PVP) into primaquine controlled release matrix system 
and to carry out In vitro investigation.
MATERIALS AND METHODS
Primaquine phosphate was supplied as gift sample from 
central drug research institute (Lucknow, India). HPMC, 
Polyvinyl pyrrolidone (PVP) K90 was procured from 
Himedia (Mumbai,India). Ethyl cellulose was procured 
from (Merck, India). All other ingredients used throughout 
the study were of IP grade and were used as received.
Preparation of sustained release matrix tablets:
Matrix tablets were prepared by wet granulation method. 
The composition of various formulations is given in table 1. 
PQ and HPMC were mixed in a polybag, and the mixture 
was passed through mesh (No. 40). Granulation was done 
using 4% solution of PVP & 8% solution of ethylcellulose 
in isopropyl alcohol. After enough cohesiveness was 
obtained the mass was extruded through mesh no 10. 
The wet granules were air dried for 4 hours thereafter 
kept in a desiccator for 12 hours at room temperature 
for complete removal of alcohol. The granules were then 
sized by mesh No. 16 and mixed with talc and magnesium 
stearate as glidant and lubricant respectively. Tablets were 
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compressed at 200 mg weight on a single station tableting 
machine (Cadmach, India) with 9-mm biconvex punches. 
Nine different formulas were developed to evaluate the 
drug release and to study the effect of auxiliary substance 
on drug release.
Evaluation of granules
Angle of Repose: The angle of repose of granules was 
determined by the funnel method. The accurately weighed 
granules were taken in a funnel. The height of the funnel 
was adjusted such that the tip of the funnel just touched 
the apex of the heap of the granules. The granules were 
allowed to flow through the funnel freely onto the graph 
paper placed on the surface. The diameter of the powder 
cone was measured and angle of repose was calculated 
using the following equation7.
tan θ = h/r      (2)
Where, h and r are the height and radius of the powder 
cone respectively.
Bulk Density: A quantity of 2 g of powder from 
each individual formula, shaken lightly to break any 
agglomerates formed and was introduced into a 10-mL 
measuring cylinder, Initial volume was observed, further 
cylinder was allowed to fall under its own weight onto 
a hard surface from the height of 2.5 cm at 2- second 
intervals. The tapping was continued until no further 
change in volume was noted. Loose bulk density (LBD) 
and tapped bulk density (TBD) were calculated using the 
following formulae8:
LBD=weight of the powder/volume of the packing  (3)
TBD= weight of the powder/tapped volume of the packing  (4)
Where, LBD= Loose bulk density; TBD= Tapped bulk 
density.
Compressibility Index: The compressibility index of the 
granules was determined by Carr’s compressibility index9
Compressibility index was determined by the same 
instrument as used for bulk density determination.
Table 1. Hydrophilic matrix tablet composition (mg)
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9
Drug 50 50 50 50 50 50 50 50 50
HPMC 50 50 50 --- --- --- --- --- ---
Na CMC 50 50 50 --- --- ---
Na alginate 50 50 50
Pvp(4%) --- q.s --- --- q.s --- --- q.s ---
Ec(8%) --- --- q.s --- --- q.s --- --- q.s
Mg stearate 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Talc upto 200 200 200 200 200 200 200 200 200
Carr´s Index (%)= [(TBD-LBD) x100]/TBD  (5)
Total Porosity: Total porosity was determined by 
measuring the volume occupied by a selected weight of a 
powder (Vbulk) and the true volume of granules (the space 
occupied by the powder exclusive of spaces greater than 
the intermolecular space)10.
Porosity (%)= (Vbulk -V)/Vbulk x100  (6)
Drug Content: An accurately weighed amount of powdered 
primaquine phosphate granules (100 mg) was extracted 
with water and the solution was filtered. The absorbance 
was measured at 222 nm after suitable dilution.
Evaluation of Tablets
Weight Variation Test: To study weight variation, 20 
tablets of each formulation were weighed using an 
electronic balance (Denver, Germany) and the test was 
performed according to the official method.
Swelling Behavior of Tablets: The extent of swelling was 
measured in terms of percentage weight gain by the tablets. 
The swelling behavior of all the formulations was studied. 
Three tablets from each formulation was kept in Petri dish 
containing phosphate buffer pH 6.8. At the end of 2, 4, 6, 
8, 10 and 12hrs tablets were withdrawn, soaked on tissue 
paper and weighed, and then percentage weight gain by 
the tablet was calculated using formula.
      (7)
Where, SI = Swelling index, Mt = Weight of tablet at time ‘t’ 
and Mo = Weight of tablet at time ‘0’.
Drug Content: Five tablets were weighed individually, and 
the drug was extracted by vortexing in water. The drug 
content was determined spectrophotometrically at 222 nm 
(Shimadzu, 1707).
Hardness and Friability: The hardness (n=6) and friability 
(n=20) of tablets of each batch, were determined using 
the MONSANTO Hardness tester and the Friability test 
apparatus (Lab India, Mumbai, India), respectively.
SI = Mt -          x 100Mo
Mo
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Invitro Release Studies: Drug release was assessed by 
dissolution test under the following conditions: n = 6 (in 
triplicate), USP type II dissolution apparatus (Lab India, 
Mumbai, India) at 50 rpm in 900 mL of phosphate buffer 
at pH 7.4 maintained at 37ºC ± 0.5ºC. Ten milliliters of the 
sample was withdrawn at regular intervals and replaced 
with the same volume of prewarmed (37ºC ± 0.5ºC) 
fresh dissolution medium. The samples withdrawn were 
filtered through whatman filter paper. The drug release 
at different time intervals was measured by UV-visible 
spectrophotometer (Shimadzu 1701, Japan) at 222 nm.
Study of Release Kinetics: In order to investigate the mode 
of release from tablets, the release data was analyzed with 
the following mathematical models:
Zero order equation; (Q = Kot)    (8)
First order equation; [In (100-Q) =In Q-K1t]   (9)
Higuchi equation;  (Q=kt1/2)   (10)
Korsmeyer and peppas equation;(Q= kptn)  (11)
Where Q is the percent of the drug release at time t,k0 
and kt are the coefficients of equation. kp is constant 
incorporating structural and geometric characteristics of 
the release device and n is the release exponent indicate 
the release mechanism.
Hixson-Crowell cube root law; (Q 0
1/3-Q t
1/3=Khc t)  (12)
Where, Qt is the amount of drug released in time t, Q0 is 
the initial amount of the drug in tablet and Khc is the rate 
constant for Hixson-Crowell rate equation.
RESULTS AND DISCUSSION
Evaluation of granules:
A granule is an aggregation of component particles that is 
held together by the presence of bonds of finite strength. 
Physical properties of granules such as specific surface 
area, shape, hardness, surface characteristics, and size can 
significantly affect the rate of dissolution of drugs contained 
in a heterogeneous formulation.  The results of angle of 
repose (<30) indicate good flow properties of the granules. 
This was further supported by lower compressibility index 
values. Generally, compressibility index up to 15% result 
indicates good to excellent flow properties.  The drug 
content in a weighed amount of granules of all formulations 
range as specified in IP. The percentage porosity values 
of the granules ranged from 26.92% to 34.25%, indicating 
close to lose packing, which further confirms uniform size 
of particles Generally, a percentage porosity value below 
26% shows that the particles in the powders are of greatly 
different sizes and a value greater than 48% shows that 
particles exist as aggregates or flocculates (table 2). 
Evaluation of tablets:
Direct compression is the preferred technique for making 
controlled release tablet formulations. However, study 
shows that when the tablet contains water soluble active 
substance , direct compression technique would be less 
effective19. PQ is a water-soluble, hydrophilic material, 
which allows quicker penetration of water in the system, 
resulting in rapid release. This characteristic release had 
been controlled by hydrophilic polymers such as HPMC, 
Sodium CMC and Sodium alginate in the system and 
further adopting aqueous granulation for making tablets. 
The results of the uniformity of weight, hardness, drug 
content, thickness, and friability of the tablets are depicted 
in table 2. All the samples of the test product complied 
with the official requirements for uniformity of weight. 
The drug content was found to be equivalent as label claim 
for PQ in all formulations. The low friability (less than 1%) 
indicates that the matrix tablets were compact and hard. 
The results were reproducible, even on tablets that had 
been stored for about 90 days at room temperature and 
70% relative humidity (table 3).
Swelling behavior of tablets:
Since hydrophilic matrices control the release through 
diffusion and erosion process by forming a gelatinous 
swollen mass, the rate of swelling and erosion is related 
and may also affect the mechanism and kinetics of drug 
release. The penetration of the dissolution medium in the 
hydrated tablets was determined. The swelling index of 
tablet at various time intervals was plotted as shown in 
figures 1. The swelling behavior followed the following 
sequence HPMC>Sodium CMC> Sodium alginate. Due to 
high swelling index HPMC could sustain the release rate 
more than Sodium CMC and sodium alginate. The swelling 
of polymers were characterized by anisotropic swelling 
phenomenon (i.e more swelling in the axial direction than 
in the radial direction on exposure to water). The reason 
for such preferential swelling in an axial direction must 
be due to the need for the directional stresses, imposed on 
polymers during tableting, to relax. The swelling capacity 
was sustained due to the presence polymeric dispersions 
of PVP & ethyl cellulose as it delays erosion process hence 
making the tablets remain intact and further sustaining 
drug release. This delay in erosion process might be due 
low solubility of PVP and EC as compared to polymer 
matrix.
Invitro Release Studies 
The invitro drug release characteristics were studied in 
Phosphate buffer pH 7.4  for a period of 24 hours using 
USP Type II dissolution apparatus at 50 rpm. Figure 2 
shows that the retarding capacity follows HPMC>Sodium 
CMC>Sodium alginate. Tablets containing HPMC (F1), 
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Table 2. Evaluation of granules.
Table 3. Physical evaluation of tablets.
Figure 1. Swelling behavior of polymers under 
dissolution conditions. Readings in triplicate.
Figure 2. Release profile of PQ from tablets prepared 
by HPMC, Sodium CMC, Sodium alginate and effect 
of other auxiliary substances. Readings in triplicate.
Ingredients Angle of repose (n=3)
Loose bulk density 
(g/ml) (n=3)








F1 24.68±0.02 0.396±0.03 0.445±0.06 11.01±0.03 34.25±0.03 97.68±0.06
F2 23.97±0.08 0.267±0.02 0.301±0.03 11.29±0.01 33.09±0.07 98.41±0.01
F3 22.73±0.04 0.407±0.05 0.485±0.05 14.08±0.02 27.21±0.02 98.62±0.03
F4 21.84±0.03 0.312±0.02 0.364±0.01 14.28±0.04 31.42±0.01 96.64±0.04
F5 23.91±0.01 0.338±0.07 0.385±0.02 12.20±0.05 28.43±0.03 98.14±0.05
F6 24.11±0.07 0.421±0.03 0.481±0.07 12.47±0.03 26.92±0.06 95.53±0.02
F7 23.95±0.02 0.219±0.04 0.248±0.03 11.69±0.02 31.74±0.04 97.77±0.01
F8 22.01±0.06 0.298±0.08 0.342±0.02 12.86±0.02 32.03±0.02 96.01±0.04






Weight variation (%) 
(n=20)
Drug content (%)
    (n=6)
F1 4.0±0.12 0.69±0.02 3.24±0.06 98.45±0.04
F2 4.2±0.81 0.78±0.04 2.45±0.02 99.89±0.56
F3 4.8±0.04 0.76±0.01 2.09±0.08 99.25±0.23
F4 4.5±0.23 0.71±0.06 3.00±0.05 100.93±0.45
F5 4.6±0.63 0.68±0.05 2.54±0.01 101.12±0.67
F6 4.0±0.21 0.85±0.03 2.16±0.04 98.81±0.78
F7 4.5±0.18 0.76±0.02 2.98±0.01 99.12±0.34
F8 4.5±0.23 0.88±0.01 2.68±0.02 99.68±0.34
F9 4.6±0.05 0.81±0.04 2.98±0.05 99.89±0.25
Sodium CMC (F4) & Sodium alginate (F7) approx 90% 
drug release after 10,6 & 5 hrs respectively. Prolonged 
release for HPMC was observed as it may due to more 
viscous solution. Formulations F4 & F7 underwent erosion 
before complete swelling could take place, resulting in 
faster release of drug. The release of the drug was further 
sustained by the addition of polymeric dispersions of 
PVP & ethyl cellulose as it delays erosion of polymers. F3 
formulation showed maximum retention and released 98% 
of the drug in 20 hrs.
Study of Release Kinetics:
In order to determine the release model which best 
describes the mechanism of drug release, the in vitro release 
data were fitted to zero order, first order and diffusion 
controlled release mechanisms according to the simplified 
higuchi model (cumulative percentage of drug released 
vs. square root of time). The release pattern of a certain 
mechanism was based on the correlation coefficient (r) 
for the parameters studied, where the highest correlation 
coefficient is preferred for the selection of mechanism of 
release. Successive substantiation of the relative legality 
of diffusion and first order models obtained by analyzing 
the data using the following equation of korsmeyer and 
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peppas (log cumulative percentage of drug released vs. log 
time)
Mt - M∞= k.tn     (13)
Where, Mt/M∞ is the fraction released by the drug at time 
t, K is a constant incorporating structural and geometric 
characteristic and n is the release exponent characteristic 
for the drug transport mechanism. Value of n=0.45 
indicates a classical fickian diffusion controlled drug 
release and the release rate is dependent on t, while 0.45< n 
<0.89 indicate anomalous (drug diffusion in the hydrated 
matrix and the polymer relaxation) transport and when n = 
0.89, the release is zero order, non fickian, indicates a case 
II relaxational release transport. The data were also plotted 
according the hixson crowell cube root law to examine the 
effect of surface area on the release mechanism.
In our experiments, the in vitro release profiles of drug 
from all the formulations could be best expressed by 
higuchi’s equation, as the plots (Figure 3) showed high 
linearity (R2: 0.954 to 0.998). Higuchi model has been used 
to explain release of water soluble or insoluble drug from 
solid matrix. Higuchi equation is followed usually when 
the release follows diffusion mechanism.  To confirm the 
diffusion mechanism, the data were fit into korsmeyer 
peppas model. All formulations F-1 to F-9 showed high 
linearity (R2: 0.977 to 0.995), with slope (n) values ranging 
from 0.47 to 0.64), which indicates drug release mechanisms 
involving a combination of both diffusion and chain 
relaxation mechanisms. The dissolution data were also 
plotted in accordance with hixson crowell cube root law, 
applicability of data (R2 = 0.970 to 0.995) indicates a change 
in surface area and diameter of tablets with the progressive 
dissolution of matrix as a function of time (table 4). 
CONCLUSION:
In this study, hydrophilic matrix tablets composed of 
HPMC, Sodium CMC & sodium alginate containing 
hydrophilic drug primaquine were prepared. HPMC, 
Sodium CMC & sodium alginate were chosen as release 
modifiers as they exhibit the property of gelation polymer. 
Effect of ethanolic solution of PVP & ethyl cellulose was 
also investigated. The release rates for primaquine from 
formulation containing HPMC matrix was significantly 
retarded as compared to other polymer matrices. The 
release was further retarded by the addition of ethanolic 
solution of PVP & ethylcellulose as they act as binder and 
lead to a formation of stiffer matrix which prevent erosion 
of the polymer, prominently releasing the drug by diffusion 
process.
ACKNOWLEDGEMENTS
The authors acknowledge central drug research institute, 
Lucknow, India for providing gift sample of primaquine 
phosphate. The authors would also like to acknowledge 
Project director, National institute for pharmaceutical 
education and research, Raebareli for providing the 
facilities to carry out this study.
REFERENCES:
1. Goodman LS, Gilman AG, Hardman JG, and Limbird LE. 
Goodman & Gilman’s the pharmacological basis of therapeutics. 
10th Ed. New York: 2003
2. Baird JK, Fryauff DJ, Hoffman SL. Primaquine for Prevention 
of Malaria in Clinical Infectious Diseases. 2003;37:1659–1667
3. Bami HL, Dhatt MS, Ahluwalia GS, Ray AP. Studies on 
Table 4. Kinetic values obtained from different plots of formulations, F1 to F9. 
Ingredients
First order Zero  order Higuchi Korsmeyer-peppas Hixson crowell
R2 R2 R2 R2 n R2
F1 0.898 0.988 0.988 0.98 0.51 0.988
F2 0.956 0.957 0.957 0.99 0.52 0.981
F3 0.948 0.954 0.954 0.97 0.56 0.991
F4 0.942 0.996 0.996 0.99 0.53 0.992
F5 0.914 0.990 0.990 0.98 0.57 0.993
F6 0.940 0.960 0.962 0.99 0.47 0.983
F7 0.948 0.991 0.991 0.98 0.64 0.993
F8 0.910 0.998 0.998 0.98 0.53 0.995
F9 0.932 0.904 0.989 0.98 0.49 0.970
Figure 4: Higuchi plot
Tahir MA, Sant S, Swati S, Awadhesh K, Sajid MA, Pattnaik GD, Farheen T, Saquib,Nadeem.
Ars Pharm. 2011; 52(3): 19-25.
25
metabolic degradation of pamaquin (plasmoquin) in monkeys. 
Indian journal of malariology. 1960; 14:1-13
4. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global 
distribution and population at risk of malaria: past, present, and 
future. Lancet Infect Dis 2004; 4(6): 327–336.
5. White NJ. The treatment of malaria. New Eng J Med. 1996; 
335(11): 800-806.
6. Klotsas EG, Andrew Lever ML. An update on malaria 
prevention, diagnosis and treatment for the returning traveler. 
Blood Reviews.2007;21(2):73-87.
7. Bhadra D, Yadav AK, Bhadra S, Jain NK. Glyco dendrimeric 
nanoparticulate carriers of primaquine phosphate for liver 
targeting. International Journal of Pharmaceutics. 2005; 295 
(1-2):221-233.
8. Green M D,  D’Souza MJ, Holbrook JM, Wirtz RA. In vitro 
and in vivo evaluation of albumin encapsulated primaquine 
diphosphate prepared by nebulization into heated oil. J 
Microencapsu. 2004;21(4):433-444.
9. Singh KK ,Vingkara SK. Formulation of antimalarial activity 
and biodistribution of oral lipid nanoemulsion of primaquine. 
International Journal of Pharmaceutics. 2008; 347(1-2):136-143.
10. Jeans CW, Heard CM. A therapeutic dose of primaquine can 
be delivered across excised human skin from simple transdermal 
patches. International Journal of Pharmaceutics.1999; 189(1):1-6.
11. Noel S, Sharma S, Shanker R, Rath SK. Primaquine induced 
differential gene expression analysis in mice liver using DNA 
microarrays. Toxicology. 2007;239(1-2):96-107.
12. Singh P, Desai SJ, Simonelli AP, Higuchi WI. Role of wetting 
on the rate of drug release from inert matrices. Journal of 
Pharmaceutical Sciences. 1968;57 (2), 217-226.
13. Sujja-areevatha J, Mundaya DL, Coxa PJ, Khan KA. 
Relationship between swelling, erosion and drug release in 
hydrophilic natural gum mini-matrix formulations. European 
Journal of Pharmaceutical Sciences. 1998; 6:207–217.
14. Colombo P. Swelling-controlled release in hydrogel matrices for 
oral route. Advanced Drug Delivery Reviews. 1993; 11(1-2):37-57
15. Siepmann J, Kranz H, Bodmeier R, Peppas NA.  HPMC-
matrices for controlled drug delivery: a new model combining 
diffusion, swelling, and dissolution mechanisms and predicting 
the release kinetics. Pharm Res. 1999;16:1748-1756.
16. Lee BJ, Ryu SG, Cui JH. Formulation and Release 
Characteristics of Hydroxypropyl Methylcellulose Matrix 
Tablet Containing Melatonin. Drug development and industrial 
pharmacy. 1999;25(4):493–501.
17. Liew CV, Chan LW, Ching AL, Sia Heng PW. Evaluation 
of sodium alginate as drug release modifier in matrix tablets. 
International Journal of Pharmaceutics. 2006; 309:25–37.
18. Emami J, Tajeddin M and Ahmadi F. Preparation and In Vitro 
Evaluation of Sustained-Release  Matrix Tablets of Flutamide 
Using Synthetic and Naturally Occurring Polymers. Iranian 
Journal of Pharmaceutical Research. 2008, 7(4):247-257.
19. Avachat A and Kotwal  V. Design and Evaluation of Matrix-
Based Controlled Release Tablets of Diclofenac Sodium and 
Chondroitin Sulphate. AAPS PharmSciTech. 2007;8 (4):E1-6
Hydrophilic polymers as release modifiers for primaquine phosphate: Effect of polymeric dispersion 
Ars Pharm. 2011; 52(3): 19-25.
